InvestorsHub Logo
Followers 8
Posts 1510
Boards Moderated 0
Alias Born 03/19/2007

Re: None

Wednesday, 04/22/2015 7:23:18 AM

Wednesday, April 22, 2015 7:23:18 AM

Post# of 7730
Interesting read from (AST)...

Gern sold their entire stem cell IP portfolio to Biotime (BTX), including two major product candidates in clinical trials - one is a cancer vaccine and the other remylinates nerve tissues. Biotime spun off Asterias as a subsidiary to continue the development of these two products both of which have mind blowing potential - if the next phases of the clinical trials continue to show positive results. BTX & GERN, to a much lesser degree, holds a substantial portion of AST shares. Many of the key people in BTX are former GERN leadership personell.


This press release came out today which, I believe, is why the stock is soaring.


http://investor.biotimeinc.com/phoenix.zhtml?c=83805&p=irol-newsArticle&ID=2038099

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent GERN News